Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
December 03 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, today announced that multiple
studies will be presented at the 2019 San Antonio Breast Cancer
Symposium (SABCS) being held Dec. 10-14, 2019 in San Antonio,
Tx.
"We are excited to present new data from several
studies at SABCS this year,” said Nicole Lambert, president of
Myriad Oncology. "Our data represents Myriad’s commitment to
advancing precision oncology for people with breast cancer and
improving outcomes.”A list of the company’s presentations at SABCS
is below. Please visit Myriad at booth #113 to learn more
about our portfolio of genetic tests for breast cancer. Follow
Myriad on Twitter via @myriadgenetics and keep up to date with
Symposium news by using the hashtag #SABCS19.
Featured Research at 2019 SABCS |
Myriad Product |
Abstract |
Author |
Poster Details |
myRisk® Hereditary
Cancer and
riskScore® |
Polygenic breast cancer risk modification in carriers of high and
intermediate risk gene mutations |
Elisha Hughes |
Poster
(P6-08-07)Saturday, Dec. 147:00-9:00 a.m. |
Cancer risks associated with pathogenic variants in the ataxia
telangiectasia mutated (ATM) gene |
Michael Hall |
Poster (P5-03-02)Friday, Dec. 135:00-7:00 p.m. |
|
EndoPredict® |
Prognostic value of EndoPredict and Oncotype Recurrence Score
according to patients’ age |
Ivana Sestak |
Poster (P5-06-04)Friday, Dec. 135:00-7:00 p.m. |
Correlation between and molecular drivers of Oncotype DX, Prosigna,
EndoPredict and Breast Cancer Index: a TransATAC study |
Richard Buus |
Poster
(P3-07-05)Thursday, Dec. 125:00-7:00 p.m. |
About Myriad myRisk® Hereditary CancerThe
Myriad myRisk Hereditary Cancer test uses an extensive number of
sophisticated technologies and proprietary algorithms to evaluate
35 clinically significant genes associated with eight hereditary
cancer sites including: breast, colon, ovarian, endometrial,
pancreatic, prostate and gastric cancers and melanoma.
About riskScore®riskScore is a
new clinically validated personalized medicine tool that enhances
Myriad’s myRisk® Hereditary Cancer test. riskScore helps to
further predict a women’s lifetime risk of developing breast cancer
using clinical risk factors and genetic-markers throughout the
genome. The test incorporates data from greater than 80 single
nucleotide polymorphisms identified through 20 years of genome wide
association studies in breast cancer and was validated in our
laboratory to predict breast cancer risk in women of European
descent. This data is then combined with a best-in-class family and
personal history algorithm, the Tyrer-Cuzick model, to provide
every patient with individualized breast cancer risk.
About EndoPredict®EndoPredict is a
second-generation, prognostic test that aids personalized treatment
planning for patients with early-stage breast cancer.
EndoPredict has been validated in over 3500 patients with
node-negative and node-positive disease and is the leading breast
prognostic in Europe. In contrast to first-generation
multigene prognostic tests, EndoPredict incorporates a 12-gene
molecular score with known prognostic factors tumor size and nodal
status. In clinical studies, EndoPredict demonstrated its
robust ability to predict recurrence risk across multiple
time-periods: 0-5, 5-10, and 5-15 years. EndoPredict provides
clinically actionable information to physicians and patients as
they consider the use of adjuvant chemotherapy and extended
endocrine therapy.
About Myriad GeneticsMyriad
Genetics Inc. is a leading precision medicine company dedicated to
being a trusted advisor transforming patient lives worldwide with
pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on five critical success
factors: building upon a solid hereditary cancer foundation,
growing new product volume, expanding reimbursement coverage for
new products, increasing RNA kit revenue internationally and
improving profitability with Elevate 2020. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.Myriad, the Myriad logo, BART,
BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight,
riskScore, Prolaris, Foresight and Prequel are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the Company’s data across multiple genetic
tests being featured at the 2019 San Antonio Breast Cancer
Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; and the
Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be
unable to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2019, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact: |
Ron Rogers(801) 584-3065rrogers@myriad.com |
Investor Contact: |
Scott Gleason(801) 584-1143sgleason@myriad.com |
|
|
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024